Five Data Barriers to Safer Small Molecule Drug Development and How To Overcome Them

Advancing small molecules from idea to candidate hinges on speed, clarity, and early high-stakes decisions. As discovery workflows grow more complex and data volumes expand, it becomes increasingly difficult to access the insights needed to accelerate R&D and advance candidates with confidence. Fragmented discovery data, limited visibility into structure-activity relationships, and safety data gaps can compromise early-stage decisions, reduce the accuracy of development models, and lead to costly late-stage setbacks. This whitepaper explores five critical data challenges slowing R&D and offers actionable strategies that support smarter design decisions in small molecule drug discovery. Download this whitepaper to learn more about: Transforming fragmented data into a unified, searchable platform that eliminates silos and streamlines information retrieval. How structural visualization and scaffold-based exploration reveal potency, selectivity, and safety trends earlier in the discovery process. Approaches for incorporating ADME and toxicity data into the design